原发性甲状旁腺功能亢进热消融治疗专家共识

2021-10-14 白求恩精神研究会内分泌和糖尿病学分会介入内分泌专业委员会 中日友好医院学报

原发性甲状旁腺功能亢进(原发甲旁亢)发病率呈上升趋势,严重影响患者的生活质量。与经典手术切除相比,原发甲旁亢热消融治疗具有微创、安全、有效等优势。相较其它肿瘤性病变,原发甲旁亢热消融治疗具有特殊性。

中文标题:

原发性甲状旁腺功能亢进热消融治疗专家共识

发布日期:

2021-10-14

简要介绍:

原发性甲状旁腺功能亢进(原发甲旁亢)发病率呈上升趋势,严重影响患者的生活质量。与经典手术切除相比,原发甲旁亢热消融治疗具有微创、安全、有效等优势。相较其它肿瘤性病变,原发甲旁亢热消融治疗具有特殊性。一方面,原发甲旁亢主要引起机体钙磷代谢紊乱,在病理、临床表现和转归方面不同于肿瘤性病变;另一方面,甲旁亢热消融治疗在技术细节、疗效评价、术后随访和干预措施等方面也有其自身特点。为推动原发甲旁亢热消融治疗工作顺利开展,为相关医生提供全面和有价值的技术细节指导,促进原发甲旁亢微创治疗的规范化,中日友好医院介入医学科在大量临床实践和科研基础上,联合国内相关领域专家,多次研讨修正,制定了本共识。 

相关资料下载:
[AttachmentFileName(sort=1, fileName=原发性甲状旁腺功能亢进热消融治疗专家共识_2021版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=801f21c00223a64e, title=原发性甲状旁腺功能亢进热消融治疗专家共识, enTitle=, guiderFrom=中日友好医院学报, authorId=0, author=, summary=原发性甲状旁腺功能亢进(原发甲旁亢)发病率呈上升趋势,严重影响患者的生活质量。与经典手术切除相比,原发甲旁亢热消融治疗具有微创、安全、有效等优势。相较其它肿瘤性病变,原发甲旁亢热消融治疗具有特殊性。, cover=https://img.medsci.cn/20211022/1634912572525_5579292.jpg, journalId=0, articlesId=null, associationId=2034, associationName=白求恩精神研究会内分泌和糖尿病学分会介入内分泌专业委员会, associationIntro=白求恩精神研究会内分泌和糖尿病学分会介入内分泌专业委员会(学组), copyright=0, guiderPublishedTime=Thu Oct 14 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">原发性甲状旁腺功能亢进(原发甲旁亢)发病率呈上升趋势,严重影响患者的生活质量。与经典手术切除相比,原发甲旁亢热消融治疗具有微创、安全、有效等优势。相较其它肿瘤性病变,原发甲旁亢热消融治疗具有特殊性。一方面,原发甲旁亢主要引起机体钙磷代谢紊乱,在病理、临床表现和转归方面不同于肿瘤性病变;另一方面,甲旁亢热消融治疗在技术细节、疗效评价、术后随访和干预措施等方面也有其自身特点。为推动原发甲旁亢热消融治疗工作顺利开展,为相关医生提供全面和有价值的技术细节指导,促进原发甲旁亢微创治疗的规范化,中日友好医院介入医学科在大量临床实践和科研基础上,联合国内相关领域专家,多次研讨修正,制定了本共识。&nbsp;</span></p>, tagList=[TagDto(tagId=100875, tagName=原发性甲状旁腺功能亢进)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=100875, guiderKeyword=原发性甲状旁腺功能亢进, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=40956, appHits=92, showAppHits=0, pcHits=465, showPcHits=40864, likes=1, shares=12, comments=4, approvalStatus=1, publishedTime=Sun Oct 24 23:14:30 CST 2021, publishedTimeString=2021-10-14, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=dajiong, createdTime=Sun Oct 24 22:39:22 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Mon Jan 01 21:20:22 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=原发性甲状旁腺功能亢进热消融治疗专家共识_2021版.pdf)])
原发性甲状旁腺功能亢进热消融治疗专家共识_2021版.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1198603, encodeId=b3431198603db, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/6b37fd61cb8947aeae427fce7764cd05/3fa8af32d5e24bf58750f7872e6f579d.jpg, createdBy=f94f5430037, createdName=天~~, createdTime=Wed Mar 02 09:15:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080619, encodeId=d8ac10806191b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:24 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080618, encodeId=449b10806185b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:18 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078800, encodeId=b10810e8800fd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58aa2052188, createdName=南超人, createdTime=Fri Dec 10 15:39:58 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2022-03-02 天~~

    #学习#学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1198603, encodeId=b3431198603db, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/6b37fd61cb8947aeae427fce7764cd05/3fa8af32d5e24bf58750f7872e6f579d.jpg, createdBy=f94f5430037, createdName=天~~, createdTime=Wed Mar 02 09:15:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080619, encodeId=d8ac10806191b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:24 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080618, encodeId=449b10806185b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:18 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078800, encodeId=b10810e8800fd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58aa2052188, createdName=南超人, createdTime=Fri Dec 10 15:39:58 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1198603, encodeId=b3431198603db, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/6b37fd61cb8947aeae427fce7764cd05/3fa8af32d5e24bf58750f7872e6f579d.jpg, createdBy=f94f5430037, createdName=天~~, createdTime=Wed Mar 02 09:15:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080619, encodeId=d8ac10806191b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:24 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080618, encodeId=449b10806185b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:18 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078800, encodeId=b10810e8800fd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58aa2052188, createdName=南超人, createdTime=Fri Dec 10 15:39:58 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2021-12-16 龙珠

    学习好资料

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1198603, encodeId=b3431198603db, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210610/6b37fd61cb8947aeae427fce7764cd05/3fa8af32d5e24bf58750f7872e6f579d.jpg, createdBy=f94f5430037, createdName=天~~, createdTime=Wed Mar 02 09:15:15 CST 2022, time=2022-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080619, encodeId=d8ac10806191b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:24 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1080618, encodeId=449b10806185b, content=学习好资料, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0eb95611909, createdName=龙珠, createdTime=Thu Dec 16 09:46:18 CST 2021, time=2021-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1078800, encodeId=b10810e8800fd, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58aa2052188, createdName=南超人, createdTime=Fri Dec 10 15:39:58 CST 2021, time=2021-12-10, status=1, ipAttribution=)]
    2021-12-10 南超人

    谢谢分享

    0

拓展阅读

2016 AAES指南:原发性甲状旁腺功能亢进的管理

美国内分泌外科协会(AAES,American Association of Endocrine Surgeons) · 2016-08-10

2021 ESA立场声明:成人原发性甲状旁腺功能亢进的手术治疗和术后随访

澳大利亚内分泌学会(ESA,Endocrine Society of Australia) · 2021-12-19

2021 ESA立场声明:成人原发性甲状旁腺功能亢进的评估和药物治疗

澳大利亚内分泌学会(ESA,Endocrine Society of Australia) · 2021-12-21